NewLink will also receive royalties from Merck, according to the report.
The experimental vaccine rVSV-EBOV was originally developed by the Public Health Agency of Canada, which will retain non-commercial rights to it.
Merck will take over vaccine development and any additional related products. The pharmaceutical company has said large-scale trials of the vaccine could begin early next year, according to the report.
The vaccine is currently undergoing early-stage trials, which test the vaccine on healthy volunteers to determine if it is safe and initiate a protective immune response, according to the report. If the results of this trial are positive, then larger late-stage trials can begin.
More articles on Ebola:
ECRI Institute creates Ebola PPE price index
Able and ready: America’s hospitals and the false threat of Ebola
New York woman’s remains test negative for Ebola
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
